Roche eyes new approach to diabetes with combo GLP-1 research

Roche ($RHHBY) is eyeing a new approach to diabetes. The Swiss drugmaker is wading into research that could top the GLP-1 diabetes-fighting class by adding one of the drugs to another imitation hormone, GIP, for a combination treatment. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.